iBio: Plants, not cell lines, for next-generation antibodies
iBio has expanded its offering to develop and manufacture Fc fusion therapeutics using it plant-based expression system.
iBio has expanded its offering to develop and manufacture Fc fusion therapeutics using it plant-based expression system.
Regenxbio says a manufacturing contract with Fujifilm Diosynth Biotechnologies will support its gene therapy candidates.
NEWS IN BRIEF
WuXi BioLogics will develop and manufacture Adagene’s antibody therapeutics for the Chinese market before expanding globally.